(Q45714390)

15 December 2017

title

Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice (English)

1 reference

15 December 2017

1 reference

4

1 reference

15 December 2017

11

1 reference

15 December 2017

Wojciech Feleszko

7

0 references

Marek Jakóbisiak

10

object named as

Marek Jakóbisiak

1 reference

15 December 2017

Cezary Wójcik

8

0 references

Ahmad Jalili

6

object named as

Ahmad Jalili

1 reference

15 December 2017

5

Małgorzata Maj

1 reference

15 December 2017

1

Adam Giermasz

1 reference

15 December 2017

Marcin Makowski

2

1 reference

15 December 2017

Ewa Kozłowska

3

1 reference

15 December 2017

Anna Dabrowska

9

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

International Journal of Cancer

15 December 2017

published in

1 reference

15 December 2017

volume

97

1 reference

15 December 2017

issue

6

1 reference

15 December 2017

page(s)

746-750

1 reference

Cell cycle-specific effects of lovastatin

15 December 2017

cites work

1 reference

Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.

21 January 2018

1 reference

A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme

21 January 2018

1 reference

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma

21 January 2018

1 reference

Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis

21 January 2018

1 reference

Short chain fatty acids in the human colon

21 January 2018

1 reference

Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication

21 January 2018

1 reference

Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer

21 January 2018

1 reference

Antitumor activity of tributyrin in murine melanoma model.

21 January 2018

1 reference

Ha-rasVal12 oncogene increases susceptibility of NIH/3T3 cells to lovastatin.

21 January 2018

1 reference

Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.

21 January 2018

1 reference

Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate

21 January 2018

1 reference

Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis

21 January 2018

1 reference

Vincristine- and cisplatin-induced apoptosis in human retinoblastoma. Potentiation by sodium butyrate

21 January 2018

1 reference

Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis

21 January 2018

1 reference

Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice

21 January 2018

1 reference

Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer

21 January 2018

1 reference

Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice

21 January 2018

1 reference

Potentiation of antitumor effects of tumor necrosis factor alpha and interferon gamma by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice

21 January 2018

1 reference

G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice

21 January 2018

1 reference

Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.

21 January 2018

1 reference

Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.10119

1 reference

15 December 2017

1 reference